Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLORA trial of fecal microbiota transfer with atezolizumab + bevacizumab in hepatocellular carcinoma
2023-506887-15-00Phase 2Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Feb 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of INTESTIFIX 001, vancomycin, atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Tumor-infiltrating CD8+ T-lymphocyte density and Incidence and severity of adverse events and serious adverse events. Planned start Feb 2024; status: authorised.
02
Drugs
INTESTIFIX 001vancomycinatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-506887-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506887-15-00.